从标准和替代方案中CFTR调节剂的药理动力学变异性
Natalie R Rose1, Ashritha R Chalamalla1, Bryan A Garcia2
1Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Alabama at Birmingham (UAB), Birmingham, AL, USA; Gregory Fleming James Cystic Fibrosis Research Center, UAB, Birmingham, AL, USA.
降低elexacaftor,tezacaftor,ivacaftor (ETI) 的剂量可能会在患有不耐受或反应较低的患者中保持囊性纤维化治疗的好处. 药理动力学数据表明,剂量调整可以有效的同时管理副作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 囊性纤维化治疗药物治疗方法
- 药物新陈代谢 药物新陈代谢
背景情况:
- 埃莱克萨卡夫托尔,特萨卡夫托尔,伊瓦卡夫托尔 (ETI) 是一种用于囊性纤维化 (CF) 的高效CFTR调节剂.
- 一些患者对标准ETI剂量有不耐受性或不充分的反应.
- 目前的ETI剂量调整缺乏强大的药理动力学指导.
研究的目的:
- 为了研究标准剂量与减少剂量的CF患者ETI血度的药理动力学变异性.
- 提供药理动力学证据,以指导临床ETI剂量调整.
主要方法:
- 一项经批准后的研究,涉及15名患有囊性纤维化症的参与者.
- 标准或减少ETI剂量方案的使用.
- 量化ETI血度使用LC-MS/MS在早晨剂量之前.
主要成果:
- 在标准和减少剂量组之间没有观察到ETI血度的显著差异,即使在剂量正常化后也是如此.
- 两组中的大多数参与者都达到与临床反应相关的度.
- 药物动力学概况表明,降低剂量是一种可行的策略.
结论:
- 减少ETI剂量可能是管理不耐受性的实用方法,同时保持CF患者的治疗疗效.
- 药理动力学数据支持用于个性化CF治疗的调整ETI剂量的使用.
更多相关视频
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
相关概念视频
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Cystic Fibrosis: Management
Sinus disease and chronic...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
